VIB - Immuno-Oncology Portfolio's Unit Acquisition

VIB - Immuno-Oncology Portfolio raised a round of funding on September 01, 2017. Investors include ThromboGenics.

VIB provides basic research in life sciences. VIB's technology transfer activities translate research results into new economic ventures which, in time, lead to new products that can be used in medici…

Articles about VIB - Immuno-Oncology Portfolio's Unit Acquisition: